뒤로
Coeptis Therapeutics Holdings Inc (COEP) 수입
COEP 주가 차트
COEP 수입
Coeptis Therapeutics Holdings Inc
$11.22
4.66%
$0.5
종가: Mar 31, 16:00:00 GMT-4
$11.49
2.4%
$0.26
애프터마켓: Mar 31, 20:00:00 GMT-4
최신 수익 결과: Q3 '24
보고됨: 2024-11-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
COEP의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Coeptis Therapeutics Holdings Inc COEP의 지난 분기 매출 실적은 어땠나요?
Coeptis Therapeutics Holdings Inc의 매출 추정치는 얼마인가요?
Coeptis Therapeutics Holdings Inc의 수익 품질 점수는 얼마인가요?
Coeptis Therapeutics Holdings Inc는 언제 수익을 보고하나요?
Coeptis Therapeutics Holdings Inc의 예상 수익은 얼마인가요?
Coeptis Therapeutics Holdings Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$10.72
시가
$11.17
일일 범위
$10.85 - $11.49
52주 범위
$6.26 - $21.41
거래량
16.1K
평균 거래량
52.5K
배당수익률
--
EPS(TTM)
-3.47
시가총액
$66.1M
COEP란 무엇인가요?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.